Diaceutics PLC Cash Flow Conversion Efficiency
Diaceutics PLC cash flow conversion efficiency. Based on the latest financial reports, Diaceutics PLC (DXRX) has a cash flow conversion efficiency ratio of 0.017x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX696.00K ≈ $84.68 USD) by net assets (GBX40.48 Million ≈ $4.93K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Diaceutics PLC (DXRX) total market value for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Diaceutics PLC (2016–2025)
Cash flow conversion efficiency of Diaceutics PLC from 2016 to 2025. This chart illustrates how Diaceutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Diaceutics PLC share price for real-time trading data and today's change.
Diaceutics PLC Cash Flow Conversion Ratio Explained
Diaceutics PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Diaceutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Diaceutics PLC ranked by their cash flow conversion efficiency. Review how much free cash does Diaceutics PLC generate to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fonix Mobile plc
LSE:FNX
|
1.074x |
|
Ragusa Minerals Ltd
AU:RAS
|
-0.314x |
|
Globavend Holdings Limited Ordinary Shares
NASDAQ:GVH
|
0.038x |
|
Elevai Labs, Inc. Common Stock
NASDAQ:ELAB
|
-0.119x |
|
Centaurus Energy Inc
V:CTA
|
-0.044x |
|
Fortune Indonesia Tbk
JK:FORU
|
-0.061x |
|
MOBILUM TECHNOLOGIES INC.
F:C0B
|
N/A |
|
Surya Oil & Gas Corp.
NASDAQ:SURY
|
0.011x |
Annual Cash Flow Conversion Efficiency for Diaceutics PLC (2016–2025)
The table below shows the annual cash flow conversion efficiency of Diaceutics PLC from 2016 to 2025. Also see Diaceutics PLC (DXRX) total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX40.48 Million ≈ $4.93K |
GBX1.50 Million ≈ $182.02 |
0.037x | +126.26% |
| 2024-12-31 | GBX39.86 Million ≈ $4.85K |
GBX651.00K ≈ $79.21 |
0.016x | -49.19% |
| 2023-12-31 | GBX40.79 Million ≈ $4.96K |
GBX1.31 Million ≈ $159.51 |
0.032x | -73.18% |
| 2022-12-31 | GBX42.51 Million ≈ $5.17K |
GBX5.10 Million ≈ $620.04 |
0.120x | +754.82% |
| 2021-12-31 | GBX40.65 Million ≈ $4.95K |
GBX570.00K ≈ $69.35 |
0.014x | +123.02% |
| 2020-12-31 | GBX40.24 Million ≈ $4.90K |
GBX253.00K ≈ $30.78 |
0.006x | +120.19% |
| 2019-12-31 | GBX20.13 Million ≈ $2.45K |
GBX-627.05K ≈ $-76.29 |
-0.031x | +91.42% |
| 2018-12-31 | GBX2.63 Million ≈ $319.93 |
GBX-954.04K ≈ $-116.08 |
-0.363x | -144.41% |
| 2017-12-31 | GBX1.88 Million ≈ $228.47 |
GBX1.53 Million ≈ $186.66 |
0.817x | +22.70% |
| 2016-12-31 | GBX1.01 Million ≈ $123.16 |
GBX674.01K ≈ $82.01 |
0.666x | -- |
About Diaceutics PLC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, that en… Read more